Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 1 | 3 | 4 |
| 2005 | 5 | 2 | 7 |
| 2006 | 5 | 8 | 13 |
| 2007 | 5 | 7 | 12 |
| 2008 | 7 | 7 | 14 |
| 2009 | 10 | 5 | 15 |
| 2010 | 16 | 14 | 30 |
| 2011 | 12 | 10 | 22 |
| 2012 | 22 | 9 | 31 |
| 2013 | 24 | 10 | 34 |
| 2014 | 17 | 9 | 26 |
| 2015 | 17 | 15 | 32 |
| 2016 | 15 | 11 | 26 |
| 2017 | 10 | 16 | 26 |
| 2018 | 15 | 11 | 26 |
| 2019 | 12 | 12 | 24 |
| 2020 | 6 | 11 | 17 |
| 2021 | 13 | 9 | 22 |
| 2022 | 2 | 11 | 13 |
| 2023 | 1 | 10 | 11 |
| 2024 | 2 | 7 | 9 |
| 2025 | 5 | 4 | 9 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. Blood Adv. 2026 Feb 24; 10(4):1023-1034.
-
Dual MAPK/VEGF inhibition for KRAS-mutated brain arteriovenous malformations. J Neurosurg. 2026 Feb 01; 144(2):452-461.
-
Current paradigm of EGFRins20 in non-small cell lung cancer: A long way forward. Med. 2025 Sep 12; 6(9):100803.
-
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025 Aug; 39(8):1797-1813.
-
Safety, Tolerability, and Pharmacokinetics of NRL-1049, a Rho-Associated Kinase Inhibitor, in Healthy Volunteers: A Phase 1, First-in-Human, Single-Ascending Dose, Randomized, Placebo-Controlled Trial. CNS Drugs. 2025 Sep; 39(9):865-877.
-
Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitis. J Crohns Colitis. 2025 Jun 04; 19(6).
-
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer. Expert Rev Anticancer Ther. 2025 Jun; 25(6):675-686.
-
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy. Biochem Pharmacol. 2025 06; 236:116850.
-
The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer. Cell Rep Med. 2025 Mar 18; 6(3):101983.
-
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study. Lung Cancer. 2025 Apr; 202:108417.